CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has been appointed to its Board of Directors effective immediately. Mr. Soland most recently served as the Chief Executive Officer of uniQure N.V. and Senior Vice President and Chief Operating Officer of ViroPharma.
“Dan is an experienced leader in the life sciences industry, with particular expertise in commercial and marketing operations in hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of KalVista. “We are pleased to have Dan join as an independent director who will further strengthen our Board. We look forward to his insights as we continue to advance our oral plasma kallikrein inhibitors for potential treatment of HAE and begin to develop our commercial and market strategy.”
“I am excited to join KalVista’s Board and collaborate with them and the leadership team to deliver potential new treatments for diseases with unmet need,” said Mr. Soland. “I look forward to working with KalVista as they advance towards becoming a commercial stage company.”
In addition to his most recent positions, Mr. Soland has an extensive background in the pharmaceutical industry. He currently serves on the Boards of Directors of Acadia Pharmaceuticals and DBV Technologies. Mr. Soland served as President of Chiron Vaccines until the acquisition of Chiron by Novartis. Prior to that, he was President and Chief Executive Officer of Epigenesis Pharmaceuticals and earlier was Vice President and Director, Worldwide Marketing Operations for GlaxoSmithKline Biologicals. Earlier in his career, Mr. Soland held positions of increasing responsibility in sales and product management at Pasteur-Merieux’s Connaught Laboratories. He holds a B.S. in Pharmacy from the University of Iowa.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company has created a structurally diverse portfolio of oral plasma kallikrein inhibitors and is advancing multiple drug candidates for HAE as well as DME. The Company has selected KVD900 as its program to be advanced as an on-demand therapy for HAE attacks and commenced a Phase 2 proof-of-concept study in HAE patients in late 2018. In DME, KalVista’s most advanced program, an intravitreally administered plasma kallikrein inhibitor known as KVD001, began a Phase 2 clinical trial in 2017 that is anticipated to complete in the second half of 2019.
For more information, please visit www.kalvista.com.
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, available funding, our cash runway and future clinical trial timing and results. Further information on potential risk factors that could affect our business and its financial results are detailed in the annual report on Form 10-K filed on July 30, 2018 and other reports as filed from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.